Γ

SynBioBeta Speaker

Victor Gotho

Enzyva

CEO

Enzyva: Precision Engineering for the Bio-EconomyThe bio-revolution is no longer about discovery; it is about performance and predictability. At Enzyva, we have moved past the experimental phase of synthetic biology to deliver high-impact, scalable solutions for the most demanding industries.The Problem: The Industrial BottleneckMost biological innovations fail when they hit the real world. They are too unstable, too inconsistent, or simply too expensive to scale. The market is tired of "lab-scale" promises that can’t meet industrial-grade KPIs.The Solution: The Enzyva EdgeEnzyva has developed a proprietary platform that optimizes biological systems for maximum output and reliability. We specialize in:Predictive Optimization: Taking the guesswork out of bio-based production.Industrial Robustness: Ensuring our solutions perform under real-world pressures.Operational Speed: Reducing the time between concept and commercialization.Strategic Leadership & ExpertiseMy expertise lies in operational strategy and the commercialization of complex technologies. I focus on the "Bio-Business" bridge. While our technical team pushes the boundaries of what's possible, my role is to ensure those breakthroughs are economically viable, scalable, and ready for market integration. I specialize in navigating the transition from a technical proof-of-concept to a robust, revenue-generating operation.Why Enzyva?We are here at SynBioBeta to connect with partners who demand more than just innovation—they demand results. We are looking for collaborators ready to integrate Enzyva’s superior biological performance into their core value chain.Enzyva: Biology at the speed of business.

Sessions Featuring

Victor

This Year

TBD

Session lineup still growing

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Featuring

Speaker Coming Soon

Previous Speakers Include